Poland· PL-100424435
Aimovig
A erenumab product containing erenumabum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Erenumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Erenumab · ATC N02CD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Erenumabum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- N02CD01
- ATC class
- Erenumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421024604
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Erenumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAimovig
- NorwayAimovigNovartis Europharm Limited (1)
- United StatesAIMOVIGAmgen Inc
- FinlandAimovigNovartis Europharm Limited
- CzechiaAIMOVIGNovartis Europharm Limited, Dublin
- BelgiumAimovig 140 mgNovartis Europharm
- IcelandAimovigNovartis Europharm Limited*
- NetherlandsAimovig 140 mg oplossing voor injectie in voorgevulde penNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aimovig
- Liechtenstein · Aimovig
- Norway · Aimovig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/986142f5-28c2-49bb-aade-d62b50a9c51f GET /v1/drugs/986142f5-28c2-49bb-aade-d62b50a9c51f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "140 mg/ml",
"packaging": "Rpz ¦ EU/1/18/1293/006 ¦ 133965\n1 amp.-strzyk. 1 ml\n07613421024604 ¦ Rpz ¦ EU/1/18/1293/004 ¦ 133966\n1 wstrzykiwacz 1 ml\nRpz ¦ EU/1/18/1293/005 ¦ 133967\n3 wstrzykiwacze 1 ml",
"substance": "Erenumabum 140 mg/ml",
"common_name": "Erenumabum",
"pl_product_id": "100424435",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about erenumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.